Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

JHOP Web Exclusives - FDA Approvals, News & Updates, Online Only

On August 17, 2017, the FDA approved inotuzumab ozogamicin (Besponsa; Pfi­zer), a targeted therapy, for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22. The FDA designated inotuzumab ozogamicin as an orphan drug and applied its priority review for this approval.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approval of inotuzumab ozogamicin was based on a randomized clinical trial of 326 patients with relapsed or refractory B-cell ALL who had received 1 or 2 previous treatments. Among the 218 evaluable patients, 35.8% of those receiving inotuzumab ozogamicin achieved complete remission that lasted a median of 8 months. Of the patients who received an alternative chemotherapy regimen, 17.4% achieved complete remission lasting a median of 4.9 months.

The common side effects reported with inotuzumab ozogamicin include thrombocytopenia, neutropenia, leukopenia, infection, anemia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, liver damage, abdominal pain, and hyper­bilirubinemia. Serious side effects attributed to the use of inotuzumab ozogamicin include myelosuppression, infusion-related reactions, and QT interval prolongation.

Inotuzumab ozogamicin was approved with a boxed warning about the risk for hepatotoxicity, including veno-occlusive disease or sinusoidal obstruction syndrome, as well as the increased mortality risk in patients who use the drug after certain stem-cell transplants.

Related Items
February 8, 2019 - FDA Approvals, News & Updates
In the News: Oncology - January 2019 published on February 1, 2019 in Breaking News, FDA Approvals, News & Updates
February 1, 2019 - FDA Approvals, News & Updates
In the News: Oncology - January 2019 published on February 1, 2019 in Breaking News, FDA Approvals, News & Updates
I. New Drugs
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
II. New Indications
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
Government Shutdown Impacts FDA Drug Approvals
In the News: Oncology - February 2019 published on January 14, 2019 in Breaking News, FDA Approvals, News & Updates
Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation
JHOP Web Exclusives published on November 30, 2018 in FDA Approvals, News & Updates
Lenvima Now Approved for Unresectable Hepatocellular Carcinoma
JHOP Web Exclusives published on November 13, 2018 in FDA Approvals, News & Updates
FDA News - September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in FDA Approvals, News & Updates
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
JHOP Web Exclusives published on July 17, 2018 in FDA Approvals, News & Updates, In the News, Online Only
Welcome to the Third Annual Oncology Guide to New FDA Approvals
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
Last modified: October 9, 2017